Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as candidates for antiangiogenesis therapy

Keyphrases

• Combinatorial Engineering 100%
• Anti-angiogenesis 100%
• Angiopoietin-2 100%
• Antiangiogenesis Therapy 100%
• Ligand-binding Domain 60%
• High Affinity 40%
• Angiogenesis 40%
• High-throughput 20%
• FDA-approved Drugs 20%
• Phosphorylation 20%
• Receptor Activation 20%
• Mechanism of Action 20%
• Structure Function 20%
• Human Cancer 20%
• Expression Stability 20%
• Engineering Approach 20%
• Multifunctional Protein 20%
• Cancer Therapy 20%
• Receptor Tyrosine Kinase 20%
• Cancer Therapeutics 20%
• Natural Proteins 20%
• Molecular Scaffold 20%
• Binding Ability 20%
• Receptor Dimerization 20%
• Cell Invasion 20%
• Tie-2 Receptor 20%
• Angiopoietin 20%
• Flow Cytometric Sorting 20%
• Mutant Library 20%
• Yeast Surface Display 20%
• Capillary Tube Formation 20%
• Combinatorial Protein Engineering 20%
• Survival Migration 20%
• Tube Cell 20%
• Multimerization 20%
• Protein-ligand 20%
• Protein Antagonist 20%
• Targeted Inhibitors 20%

Biochemistry, Genetics and Molecular Biology

• Binding Domain 100%
• Antiangiogenic Activity 100%
• Angiogenesis 66%
• Eicosanoid Receptor 33%
• Dimerization 33%
• Surface Property 33%
• Receptor Tyrosine Kinase 33%
• Structure Activity Relation 33%
• Cell Invasion 33%
• Angiopoietin-2 33%
• Angiopoietin Receptor 33%
• Angiopoietin 33%
• Protein Engineering 33%
• Protein Ligand 33%
• Multimerization 33%